Abstract
This review summarizes pathogenic mechanisms leading to the development of atherosclerosis in diabetes. Contributing factors to endothelial dysfunction including nitric oxide, prostaglandins, oxidative stress, and pro-inflammatory mediators as well as hemodynamic flow changes are described. How factors contributing to endothelial dysfunction lead to changes in lipoprotein levels and to modification of lipoproteins as well as formation of modified lipoprotein immune complexes and how that contribute to foam cell formation is also detailed. New chapters were added on the novel role of sphingolipids in the development of atherosclerosis in diabetes and how microRNAs can influence the several pathogenic mechanisms leading to accelerated development of atherosclerosis in diabetes. The inflammatory component of atherosclerosis was also reviewed by examining macrophage activation by modified lipoproteins and modified LDL immune complexes, reviewing release of cytokines and growth factors and atheroma expansion as well as metalloproteinases and plaque rupture. Finally, thrombi formation and alterations in platelet aggregation and abnormalities in the clotting and fibrinolytic system were discussed. Overall this chapter offers an update on the contributing factors and mechanisms leading to accelerated development of atherosclerosis in diabetes and provides a glimpse on the complexity and multifactorial nature of the process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Nievelstein PFEM, Fogelman AM, Frank FS, Mottino G. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of LDL: a deep-etch and immunolocalization study of rapidly frozen tissue. Arterioscler Thromb. 1991;11:1795–805.
Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW. Monocyte transmigration induced by modification of low-density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039–46.
Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM. The role of the Gro family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest. 1994;94:1968–73.
Rajavashisth TB, Andalibi A, Territo MD, Berliner JA, Naveb M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature. 1990;344:254–7.
Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292–301.
Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979;32:213–8.
Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of LDL leads to cholesterol ester accumulation in human monocytes/macrophages. Proc Natl Acad Sci U S A. 1980;77:2214–8.
Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003;10:499–505.
Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF. DCCT/EDIC Research Group. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002;105:81–92.
Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009;50(Suppl):S91–6.
Hannun Y, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175–91.
Eich C, Manzo C, de Keijzer S, Bakker G-J, Reinieren-Beeren I, García-Parajo MF, Cambi A. Changes in membrane sphingolipid composition modulate dynamics and adhesion of integrin nanoclusters. Sci Rep. 2016;6:20693.
Jiang X-C, Jing L. Sphingolipid metabolism and atherosclerosis. Handb Exp Pharmacol. 2013;216:133–46.
Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF. DCCT/EDIC Research Group. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014;63(10):1287–95.
Lopes-Virella MF, Baker NL, Hunt KJ, Hammad SM, Arthur J, Virella G, Klein RL. DCCT/EDIC Research Group. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019;13(3):481–91.
Fernández-Hernando C, Suárez Y. MicroRNAs in endothelial cell homeostasis and vascular disease. Curr Opin Hematol. 2018 May;25(3):227–36.
Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol. 1998;18:677–85.
Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, García-Cardeña G, Gimbrone MA. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis- susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci U S A. 2004;101:14871–6.
Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–36.
La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol. 2019;26(2 Suppl):15–24.
Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, Viberti GC. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes. 2000;49:2170–7.
La Sala L, Cattaneo M, De Nigris V, Pujadas G, Testa R, Bonfigli AR, Genovese S, Ceriello A. Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovasc Diabetol. 2016;15:71.
La Sala L, Mrakic-Sposta S, Micheloni S, Prattichizzo F, Ceriello A. Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidantresponses in cellular glucose variability. Cardiovasc Diabetol. 2018;17:105.
Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation. 2007;115:2178–87.
Sessa WC. eNOS at a glance. J Cell Sci. 2004;117:2427–9.
Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Phys. 1994;266:C628–36.
Gimbrone MA, García-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol. 2013;22:9–15.
Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, Udvardy M. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res. 1997;86:173–80.
Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–42.
Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A. 1992;89:444–8.
Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2001;98:4202–8.
Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med. 1997;185:601–7.
Kang-Decker N, Cao S, Chatterjee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V. Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci. 2007;120(Pt 3):492–501.
Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O’Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;115:139–50.
Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science. 1998;279:234–7.
Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034–7.
Haldar SM, Stamler JS. S-nitrosylation: integrator of cardiovascular performance and oxygen delivery. J Clin Invest. 2013;123:101–10.
Hess DT, Stamler JS. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem. 2012;287:4411–8.
Hogman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet. 1993;341:1664–5.
Kawabata A. Evidence that endogenous nitric oxide modulates plasma fibrinogen levels in rat. Br J Pharmacol. 1996;117:236–7.
Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996;97:979–87.
Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510–6.
McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771–6.
Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial-derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992;89:10–8.
Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric oxide synthase from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–9.
Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene disrupted mice. Science. 2001;293:2449–52.
Ku Lencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, Dombkowski D, Atkinson WJ, Han F, Preffer F, Rosenzweig A, Sessa WC, Gimbrone MA, Ertl G, Huang PL. Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol. 2004;286:C1195–202.
Huang PL. Lessons learned from nitric oxide synthase knockout animals. Semin Perinatol. 2000;24:87–90.
Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001;104:448–54.
Scherrer U, Randin D, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest. 1994;94:2511–5.
Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris prospective study. Diabetes Care. 1991;14:461–9.
Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorgani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischaemic heart disease. N Engl J Med. 1996;334:952–7.
The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:997–1017.
UK Prospective Diabetes Study Group. Lancet. 1998;353:854–65.
Baron AD. Insulin and the vasculature – old actors, new roles. J Investig Med. 1996;44:406–12.
Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71B–4B.
Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427–51.
Jessup W, Dean RT. Autoinhibitor of murine macrophage mediated oxidation of LDL by nitric oxide synthesis. Atherosclerosis. 1993;101:145–55.
Ischiropoulos H, al Mehdi A. Peroxynitrate-mediated oxidative protein modifications. FEBS Lett. 1995;364:279–82.
Bhatia S, Shukla R, Venkata MS, Gambhir J, Madhava PK. Antioxidant status, lipid peroxidation and nitric oxide end prodicts in patients with type 2 diabetes mellitus with nephropathy. Clin Biochem. 2003;36:557–62.
Moncada S. Biological importance of prostacyclin. Br J Pharmacol. 1982;76:3–31.
Colwell JA, Lopes-Virella MF, Winocour PD, Halushka PV. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. In: Levin ME, O’Neal LW, editors. The diabetic foot. 4th ed. St. Louis, MO: Mosby-Year Book; 1988. p. 51–70.
Sekiguchi N, Umeda F, Masakado M, Ono Y, Hashimoto T, Nawata H. Immunohistochemical study of prostacyclin-stimulating factor (PSF) in the diabetic and atherosclerotic human coronary artery. Diabetes. 1997;46:1627–32.
Umeda F, Masakado M, Takei A. Difference in serum-induced prostacyclin production by cultured aortic and capillary endothelial cells. Prostaglandins Leukot Essent Fat Acids. 1997;56:51–5.
Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, Mohamed N. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract. 2014;2014:382–93.
Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019;176(8):1038–50.
Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4:132–54.
Ahmetaj-Shala B, Kirkby NS, Knowles R, Al’Yamani M, Mazi S, Wang Z, et al. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation. 2015;131:633–42.
Toda N, Bian K, Akiba T, Okamura T. Heterogeneity in mechanisms of bradykinin action in canine isolated blood vessels. Eur J Pharmacol. 1987;135:321–9.
Briner VA, Tsai P, Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol Renal Fluid Electrolyte Physiol. 1993;264:F322–7.
Greene EL, Velarde V, Jaffa AA. Role of reactive oxygen species in bradykinin induced mitogen-activated protein kinase and c-fos induction in vascular cells. Hypertension. 2000;35:942–7.
Velarde V, Ullian ME, Mornelli TA, Mayfield RK, Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol Cell Physiol. 1999;277:C253–61.
Douillet CD, Velarde V, Christopher JT, Mayfield RK, Trojanowska ME, Jaffa AA. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-® and MAPK. Am J Physiol Heart Circ Physiol. 2000;279:H2829–37.
Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey TW, Schmaier AH. DCCT/EDIC Study Group. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes. 2003;52:1215–12221.
Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol. 2002;2:1771–9.
Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield R, Jaffa AA. Regulation of B2 kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000;280:H1537–46.
Takahashi K, Ghater MA, Lam HC, O’Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990;33:306–50.
Metsarinne K, Saijonmaa O, Yki-Jarvinen H, Fyhrquist F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism. 1994;43:878–82.
Hattori Y, Kasai K, Nakamura T, Emoto T, Shimoda S. Effects of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism. 1991;40:165–9.
Anfossi G, Cavalot F, Massucco P, Mattiello L, Mularoni E, Hahn A, Trovati M. Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells. Metabolism. 1993;42:1081–3.
Park K, Mima A, Li Q, Rask-Madsen C, He P, Mizutani K, Katagiri S, Maeda Y, Wu I-H, Khamaisi M, Preil SR, Maddaloni E, Sørensen D, Rasmussen LM, Huang PL, King GL. Insulin decreases atherosclerosis by inducing endothelin receptor B expression. JCI Insights. 2016;1(6):e86574.
Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, Yamaguchi I. Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation. 2002;106:1991–8.
Sachidanandam K, Portik-Dobos V, Harris AK, Hutchinson JR, Muller E, Johnson MH, Ergul A. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes. 2007;56:2753–8.
Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Yoshikawa J. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S84–9.
Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, Egido J. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res. 2005;97:125–34.
Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88:2923–8.
Iwasa S, Fan J, Shimokama T, Nagata M, Watanabe T. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis. 1999;146:93–100.
Kamata K, Ozawa Y, Kobayashi T, Matsumoto T. Effect of long-term streptozotocin-induced diabetes on coronary vasoconstriction in isolated perfused rat heart. J Smooth Muscle Res. 2008;44:177–88.
Matsumoto T, Ozawa Y, Taguchi K, Kobayashi T, Kamata K. Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. Peptides. 2010;31:346–53.
Verma S, Arikawa E, Lee S, Dumont AS, Yao L, McNeill JH. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol. 2002;80:980–6.
Katakam PV, Snipes JA, Tulbert CD, Mayanagi K, Miller AW, Busija DW. Impaired endothelin-induced vasoconstriction in coronary arteries of Zucker obese rats is associated with uncoupling of [Ca2+]i signaling. Am J Phys Regul Integr Comp Phys. 2006;290:R145–53.
Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med. 2006;231:653–95.
Lee DL, Wamhoff BR, Katwa LC, Reddy HK, Voelker DJ, Dixon JL, Sturek M. Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin. J Pharmacol Exp Ther. 2003;306:132–40.
Colwell JA, Jokl R. Clotting disorders in diabetes. In: Porte D, Sherwin R, Rifkin H, editors. Diabetes mellitus: theory and practice. 5th ed. Norwalk, CT: Appleton and Lange; 1997. p. 1543–57.
Colwell JA, Winocour PD, Lopes-Virella MF. Platelet function and platelet interactions in atherosclerosis and diabetes mellitus. In: Rifkin H, Porte D, editors. Diabetes mellitus: theory and practice. New York, NY: Elsevier; 1989. p. 249–56.
Uedelhoven WM, Rutzel A, Meese CO, Weber PC. Smoking alters thromboxane metabolism in man. Biochim Biophys Acta. 1991;108:197–201.
Davi G, Averna M, Catalano I, Barnagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type II a hypercholesterolemia. Circulation. 1992;85:1792–8.
Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400–6.
Davi G, Gresele P, Violi F, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular disease per se, are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69–75.
Martin W. The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes. Med Hypotheses. 1984;15(3):305–22.
Tada M, Kuzuya T, Inoue M, Kodama K, Mishima M, Yamada M, Inui M. H Abe Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris. Circulation. 1981;64(6):1107–15.
Smyth EM. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol. 2010;5(2):209–19.
Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60(4):577–84.
Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.
Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev. 2004;36:363–75.
Pritchard KA Jr, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem. 2001;276:17621–4.
Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Phys. 1993;265:E783–93.
Folcick VA, Nivar-Aristy RA, Krajewski LP, Cathcart MC. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest. 1995;96:504–10.
Benz D, Mol JM, Ezaki M, Mori-Ito MN, Zelan I, Miyanohara A, Friedmann T, Parthasarathy S, Steinberg D, Witztum JL. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J Biol Chem. 1995;270:5191–7.
Scheidegger K, Butler JS, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem. 1997;272:21609–15.
Patricia MK, Natarajan R, Dooley AN, Hernandez F, Gu JL, Berliner JA, Rossi JJ, Nadler JL, Meidell RS, Hedrick CC. Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ Res. 2001;88:659–65.
Patricia MK, Kim JA, Harper CM, Shih PT, Berliner JA, Natarajan R, Nadler JL, Hedrick CC. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2615–22.
Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med. 2000;28:1708–16.
Reglero-Real N, Colom B, Bodkin JV, Nourshargh S. Endothelial cell junctional adhesion molecules: role and regulation of expression in inflammation. Arterioscler Thromb Vasc Biol. 2016;36(10):2048–57.
Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990;136:1229–33.
Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–15.
Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21:103–15.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620–4.
Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin dependent diabetes mellitus. Diabet Med. 1997;14:423–32.
De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;39:325–42.
O’Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest. 1993;92:945–51.
Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223–9.
Poston RN, Haskard DO, Croucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665–73.
Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF. DCCT/EDIC Group of Investigators. Longitudinal association between endothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC cohort. Diabetes Care. 2025;38:1281–9.
Pigott R, Dillon LP, Hemingway IH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584–9.
Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1 and VCAM-1: pathological significance. Ann NY Acad Sci. 1992;667:324–31.
Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes. 1992;41:1668–71.
Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycemic control. Thromb Haemost. 1994;72:979–84.
Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes. 1997;46:2096–101.
Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachorzewska-Gajewska H, Stepien A. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism. 2002;51:733–6.
Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med. 2002;19:822–6.
Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P-and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med. 2002;13:185–9.
Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, Emoto M, Shoji T, Tahara H, Inaba M, Hino M, Shioi A, Miki T, Nishizawa Y. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation. 2003;108:524–9.
Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986;124:179–85.
Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–90.
Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J, Van Dyke TE. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015;35:1123–33.
Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM01) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447–56.
Virella G, Munoz Jose F, Galbraith Gillian MP, Gisinger C, Chassereau C, Virella MF. Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol. 1995;75:179–89.
Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol. 2022;11:332–8.
Beekhuizen H, van Furth R. Monocyte adherence to human vascular endothelium. Leukoc Biol. 1993;54:363–78.
Pohlman TH, Staness KA, Beatty PG, Oehs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor a increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986;136:4548–53.
Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF, Gimbrone MA. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress responsive element. Proc Natl Acad Sci U S A. 1993;90:4591–5.
Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG. Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappa B binding. J Biol Chem. 2004;279:163–8.
Korenaga R, Ando J, Kosaki K, Isshiki M, Takada Y, Kamiya A. Negative transcriptional regulation of theVCAM-1 gene by fluid shear stress in murine endothelial cells. Am J Phys. 1997;273:C1506–15.
Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA, García-Cardeña G. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest. 2006;116:49–58.
Atkins GB, Simon DI. Interplay between NF-κB and Kruppel-like factors in vascular inflammation and atherosclerosis: location, location, location. J Am Heart Assoc. 2013;2:e000290.
Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J Clin Invest. 1995;95:1363–9.
Le NT, Takei Y, Izawa-Ishizawa Y, Heo KS, Lee H, Smrcka AV, Miller BL, Ko KA, Ture S, Morrell C, Fujiwara K, Akaike M, Abe J. Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J Immunol. 2014;193:3803–15.
Ohnesorge N, Viemann D, Schmidt N, Czymai T, Spiering D, Schmolke M, Ludwig S, Roth J, Goebeler M, Schmidt M. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J Biol Chem. 2010;285:26199–210.
Dai G, Vaughn S, Zhang Y, Wang ET, Garcia-Cardena G, Gimbrone MA. Biomechanical forces in atherosclerosis resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circ Res. 2007;101:723–33.
Hsieh CY, Hsiao HY, Wu WY, Liu CA, Tsai YC, Chao YJ, Wang DL, Hsieh HJ. Regulation of shear-induce nuclear translocation of the Nrf2 transcription factor in endothelial cells. J Biomed Sci. 2009;16(1):12.
Blagovic K, Kim LY, Voldman J. Microfluidic perfusion for regulating diffusible signaling in stem cells. PLoS One. 2011;6:e22892.
Fledderus JO, Boon RA, Volger OL, Hurttila H, Ylä-Herttuala S, Pannekoek H, Levonen AL, Horrevoets AJ. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:1339–46.
Boon RA, Horrevoets AJ. Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie. 2009;29:39–40, 41–3.
Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA, García-Cardeña G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem. 2005;280:26714–9.
Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, Kumar A, Jain MK. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720–6.
Atkins GB, Wang Y, Mahabeleshwar GH, Shi H, Gao H, Kawanami D, Natesan V, Lin Z, Simon DI, Jain MK. Hemizygous deficiency of Krüppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008;103:690–3.
Schober A, Nazari-Jahantigh M, Weber C. MicroRNA mediated mechanisms of the cellular stress response in atherosclerosis. Nat Rev Cardiol. 2015;12:361–74.
Yan MS, Marsden PA. Epigenetics in the vascular endothelium: looking from a different perspective in the epigenomics era. Arterioscler Thromb Vasc Biol. 2015;35:2297–306.
Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107:13450–5.
Qin X, Wang X, Wang Y, Tang Z, Cui Q, Xi J, Li YS, Chien S, Wang N. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A. 2010;107:3240–4.
Wang KC, Nguyen P, Weiss A, Yeh YT, Chien HS, Lee A, Teng D, Subramaniam S, Li YS, Chien S. MicroRNA-23b regulates cyclin-dependent kinase-activating kinase complex through cyclin H repression to modulate endothelial transcription and growth under flow. Arterioscler Thromb Vasc Biol. 2014;34:1437–45.
Chen K, Fan W, Wang X, Ke X, Wu G, Hu C. MicroRNA-101 mediates the suppressive effect of laminar shear stress on mTOR expression in vascular endothelial cells. Biochem Biophys Res Commun. 2012;427:138–42.
Wu W, Xiao H, Laguna-Fernandez A, Villarreal G, Wang KC, Geary GG, Zhang Y, Wang WC, Huang HD, Zhou J, Li YS, Chien S, Garcia-Cardena G, Shyy JY. Flow dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation. 2011;124:633–41.
Fan W, Fang R, Wu X, Liu J, Feng M, Dai G, Chen G, Wu G. Shear-sensitive microRNA-34a modulates flow-dependent regulation of endothelial inflammation. J Cell Sci. 2015;128:70–80.
Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol. 2012;32:979–87.
Loyer X, Potteaux S, Vion AC, Guérin CL, Boulkroun S, Rautou PE, Ramkhelawon B, Esposito B, Dalloz M, Paul JL, Julia P, Maccario J, Boulanger CM, Mallat Z, Tedgui A. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114:434–43.
Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14:249–56.
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DYR, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272–84.
Agrawal S, Chaqour B. MicroRNA signature and function in retinal neovascularization. World J Biol Chem. 2014;5:1–11.
Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810–7.
La Sala L, Mrakic-Sposta SM, Prattichizzo F, Ceriello A. Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. Cardiovasc Diabetol. 2018;17(1):105.
Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNAmiR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103:12481–6.
Wang HJ, Huang YL, Shih YY, et al. MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting. NAPDH oxidase 4 expression. Mediat Inflamm. 2014;2014:379537.
Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KAM, Cooper ME, Godson C, Kantharidis P. Protective effect of let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis. Diabetes. 2017;66(8):2266–77.
Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek M. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol. 1999;19:2981–92.
Renard CB, Suzuki LA, Kramer F, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE. A new murine model of diabetes-accelerated atherosclerosis. Diabetes. 2002;51(Suppl 2):724.
Simionescu MD, Popov A, Hasu SM, Costache G, Faitar S, Vulpanovici A, Stancu C, Stern D, Simionescu N. Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model. The hyperlipemic-hyperglycemic hamster. Am J Pathol. 1996;148:997–1014.
McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995;15:431–40.
McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of non-lipid risk factors on atherosclerosis in youth with a favorable lipid profile. Circulation. 2001;103:1546–50.
Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimaki T, Solakivi T, Ronnemaa T, Raitakari OT. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes. 2002;51:493–8.
Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. LDL metabolism by macrophages activated with LDL immune complexes: a possible mechanism of foam cell formation. J Exp Med. 1988;168:1041–59.
Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991;11:1356–67.
Laakso M, Pyorala K. Lipid and lipoprotein abnormalities in diabetic patients with peripheral vascular disease. Atherosclerosis. 1988;74:55–63.
Lopes-Virella MF, Stone PG, Colwell JA. Serum high density lipoprotein in diabetes. Diabetologia. 1977;13:285–91.
Lopes-Virella MF, Wohltmann HJ, Mayfield RK, Laodholt CB, Colwell JA. Effect of metabolic control on lipid, lipoprotein and apolipoprotein levels in 55 insulin-dependent diabetic patients: a longitudinal study. Diabetes. 1983;32:20–5.
Reaven GM, Javorski WC, Reaven EP. Diabetic hypertriglyceridemia. Am J Med Sci. 1975;269:382–9.
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-year incidence of atherosclerotic vascular disease in relation of general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27–36.
Nikilla EA. High density lipoproteins in diabetes. Diabetes. 1981;30:82–7.
Semenkovich CF, Ostlund RE Jr, Schechtman KB. Plasma lipids in patients with type I diabetes mellitus: influence of race, gender and plasma glucose control: lipids do not correlate with glucose control in black women. Arch Intern Med. 1989;149:51–6.
Klein RL, Lyons TJ, Lopes-Virella MF. Metabolism of very low and low density lipoproteins isolated from normolipidaemic type II (non-insulin dependent) diabetic patients by human monocyte-derived macrophages. Diabetologia. 1990;33:299–305.
Klein RL, Lyons TJ, Lopes-Virella MF. Interaction of VLDL isolated from type I diabetic subjects with human monocyte-derived macrophages. Metabolism. 1989;38:1108–14.
Lopes-Virella MF, Sherer GK, Lees AM, Wohtmann MR, Sagel J, LeRoy EC, Colwell JA. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type I (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982;22:430–6.
Hiramatsu K, Bierman EL, Chair A. Metabolism of LDL from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts. Diabetes. 1985;34:8–14.
Bagdade JD, Subbaiah PV. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes. 1989;38:1226–30.
Bagdade JD, Buchanan WE, Kuusi T, Taskinen MR. Persistent abnormalities in lipoprotein composition in non-insulin dependent diabetes after intensive insulin therapy. Arteriosclerosis. 1990;10:232–9.
James RW, Pometta D. The distribution profiles of very low and low density lipoproteins in poorly controlled male, type II (non-insulin dependent) diabetic patients. Diabetologia. 1991;34:246–52.
James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes. 1990;39:1158–64.
Stein Y, Glangeaud MC, Fainaru M, Stein O. The removal of cholesterol from aortic smooth muscle cells in culture and Landschutz ascites cell fractions of human high density apoproteins. Biochim Biophys Acta. 1975;380:106–18.
Fielding DF, Reaven GM, Fielding PE. Human non-insulin dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by immunoabsorption of apolipoprotein E. Proc Natl Acad Sci U S A. 1982;79:6365–9.
Fielding CJ, Reaven GM, Liu G, Fielding PE. Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin dependent diabetes mellitus: its role in the inhibition of cholesteryl ester transfer. Proc Natl Acad Sci U S A. 1984;81:2512–6.
Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR. Abnormal composition of high-density lipoproteins in non-insulin dependent diabetics. Diabetes. 1982;31:126–31.
Uusitupa M, Siitonen O, Voutilainen E, Aro A, Hersio K, Pyorala K, Penttila I, Ehnholm C. Serum lipids and lipoproteins in newly diagnosed non-insulin dependent (type II) diabetic patients, with special reference to factors influencing HDL-cholesterol and triglyceride levels. Diabetes Care. 1986;9:17–22.
Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol. 1989;130:632–45.
Ledl F, Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Eng. 1990;29:565–94.
Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe ST, Baynes JW. Glycation, glycoxidation and cross-linking of collagen by glucose. Kinetics, mechanisms and inhibition of late stages. Diabetes. 1994;43:676–83.
Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end-product, N (carboxymethyl) lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271:9982–6.
Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. Quantitation of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human LDL. Biochem J. 1997;322:317–25.
Schleicher E, Deufel T, Wieland OH. Non-enzymatic glycation of human serum lipoproteins. FEBS Lett. 1987;129:1–4.
Lyons TJ, Patrick JS, Baynes JW, Colwell JA, Lopes-Virella MF. Glycation of low density lipoprotein in patients with type 1 diabetes: correlations with other parameters of glycemic control. Diabetologia. 1986;29:685–9.
Pietri A, Dunn FL, Raskin P. The effect of improved diabetic control on plasma lipid and lipoprotein levels. A comparison of conventional therapy and subcutaneous insulin infusion. Diabetes. 1980;29:1001–5.
Abrams JJ, Ginsberg H, Grundy SM. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes. 1982;31:903–10.
Sasaki J, Cottam GL. Glycation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta. 1982;713:199–207.
Steinbrecher UP, Witztum JL. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33:130–4.
Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988;37:550–7.
Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization and metabolism of the glycated and non-glycated subfractions of low density lipoproteins isolated from type I diabetic patients and non-diabetic subjects. Diabetes. 1995;44:1093–8.
Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF. Enhancement of platelet aggregation by low density lipoproteins from IDDM patients. Diabetes. 1988;37:1652–7.
Bucala R, Makita Z, Koschinsky T, Cerami, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90:6434–8.
Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of LDL by a superoxide-dependent pathway. J Clin Invest. 1994;94:771–8.
Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173:932–9.
Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938–41.
Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 1994;43(8):1010–4.
Jenkins AJ, Klein RL, Chassereau CH, Hermayer KL, Lopes-Virella MF. LDL from Patients with Well Controlled IDDM is not More Susceptible to In Vitro Oxidation. Diabetes. 1996;45:762–7.
Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215–8.
Rosenfeld ME, Palinski W, Yla-Herttula S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336–49.
Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725–9.
Palinski W, Koschinsky T, Butler S, Miller E, Vlassara H, Cerami A, Witztum JL. Immunological evidence for the presence of AGE in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol. 1995;15:571–82.
Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827–35.
Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959–72.
Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to LDL oxidation and coronary atherosclerosis in man. Lancet. 1991;339:1183–6.
Chiu HC, Jeng JR, Shieh SM. Increased oxidizability of plasma LDL from patients with coronary heart disease. Biochim Biophys Acta. 1994;225:200–8.
Andrews B, Burnand K, Paganga G, Browse N, Rice-Evans C, Sommerville K, Leake D, Taub N. Oxidizability of LDL in patients with carotid or femoral artery atherosclerosis. Atherosclerosis. 1995;112:77–84.
Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 1994;108:S21–9.
Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci U S A. 1991;88:6457–61.
Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992;89:10316–20.
Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, Lyons TJ, Jenkins AJ, Baynes JW, Thorpe SR. N-(carboxymethyl) ethanolamine: a biomarker of phospholipid modification by the Maillard Reaction in vivo. J Biol Chem. 1997;272:17473–9.
Pushkarsky T, Rourke L, Spiegel LA, Seldin MF, Bucala R. Molecular characterization of a mouse genomic element mobilized by advanced glycation endproduct modified-DNA (AGE-DNA). Mol Med. 1997;3:740–9.
Que X, Hung M-Y, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Mååttå A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;558(7709):301–6.
Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiederman C, Oberthaker S, Xu Q, Wiztum JL, Tsimikas S. Oxidized phospholipids, lipoprotein(a), Lipoprotein-associated phospholipase activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–95.
Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark K, Weger S, Oberhollenzer F, Witzum JL. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease. J Am Coll Cardiol. 2006;47(11):2219–28.
Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018;187:1–9.
Shu H, Peng Y, Hang W, Nie J, Zhou N, Wang DW. The role of CD36 in cardiovascular disease. Cardiovasc Res. 2022;118:115.
Yao S, Tian H, Miao C, Zhang D-W, Zhao L, Li Y, Yang N, Jiao P, Sang H, Guo S, Wang Y, Qin S. D4F alleviates macrophage-derived foam cell apoptosis by inhibiting CD36 expression and ER stress-CHP pathway. J Lipid Res. 2015;56(4):836–47.
Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low-density lipoprotein. Arteriosclerosis. 1990;10:325–35.
Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–7.
Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, Yla-Herttuala S, Luoma JS, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:23–7.
Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:204–9.
Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 1995;44:60–6.
Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993;23:95–101.
Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with corocnary artery disease. Clin Chim Acta. 1995;238:1–10.
Leinonen JS, Rantalaiho V, Laippala P, Wirta O, Pasternack A, Alho H, Jaakkola O, Yla-Herttuala S, Koivula T, Lehtimaki T. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic Res. 1998;29:137–41.
Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia. 1998;41:350–6.
Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999;90:165–72.
Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol. 2001;21:269–74.
Shaw PX, Horkko S, Chang MK, Curtiss L, Palinski W, Silverman GJ, Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105:1731–40.
Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247:371–80.
Hansson GK. Vaccination against atherosclerosis: science or fiction? Circulation. 2002;106:1599–601.
Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000;95:135–44.
Virella G, Thorpe S, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF, the DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end-products of human low density lipoprotein. J Lipid Res. 2003;443:487–93.
Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol. 2001;21:101–7.
Szondy E, Lengyel E, Mezey Z, Fust, Gero S. Occurrence of anti-low-density lipoprotein antibodies and circulating immune complexes in aged subjects. Mech Ageing Dev. 1985;29:117–23.
Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol. 1990;52:300–8.
Atchley D, Lopes-Virella MF, Zheng D, Virella G, DCCT/EDIC Research Group. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002;45:1562–71.
Lopes-Virella M, Virella G. Modified LDL immune complexes and cardiovascular disease. Curr Med Chem. 2019;26(9):1680–92.
Virella G, Lopes-Virella MF. The role of the immune system in the pathogenesis of diabetic complications. Front Endocrinol. 2014;5:126.
Gisinger C, Virella GT, Lopes-Virella MF. Erthrocyte-bound low density lipoprotein (LDL) immune complexes lead to cholesteryl ester accumulation in human monocyte derived macrophages. Clin Immunol Immunopathol. 1991;59:37–52.
Lopes-Virella MF, BinZafar N, Rackley S, Takei A, LaVia M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the FcγR I. Atherosclerosis. 1997;135:161–70.
Huang Y, Ghosh MJ, Lopes-Virella MF. Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes. J Lipid Res. 1997;38:110–20.
Hunt KJ, Baker N, Cleary P, Backlund J-Y, Lyons T, Jenkins A, Virella G, Lopes-Virella MF. DCCT/EDIC Research Group. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013;231(2):315–22.
Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G. DCCT/EDIC Research Group. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011;214(2):462–7.
Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Gao X, Lachin JM. DCCT/EDIC Research Group. Immune complexes and the risk of CVD in type 1 diabetes. Diabetes. 2019;68(9):1853–60.
Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011;60(2):582–9.
Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T, VADT Investigators. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012;224(2):526–31.
Sasset L, Zhang Y, Dunn TM, Di Lorenzo A. Sphingolipid de novo biosynthesis: a rheostat of cardiovascular homeostasis. Trends Endocrinol Metab. 2016;27:807–19.
Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20:2614–8.
Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol. 1996;16:4–11.
Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455–64.
Knapp M, Zendzian-Piotrowska M, Błachnio-Zabielska A, Zabielski P, Kurek K, Górski J. Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. Basic Res Cardiol. 2012;107(6):294.
Jeong TS, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998;101:905–12.
Zhao YR, Dong JB, Li Y, Wu MP. Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice. Life Sci. 2012;90:867–73.
Kasumov T, Li L, Li M, Gulshan K, Kirwan JP, Liu X, Previs S, Willard B, Smith JD, McCullough A. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One. 2015;10:e0126910.283.
Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, März W, Scharnagl H, Stojakovic T, Vlachopoulou E, Lokki ML, Nieminen MS, Klingenberg R, Matter CM, Hornemann T, Jüni P, Rodondi N, Räber L, Windecker S, Gencer B, Pedersen ER, Tell GS, Nygård O, Mach F, Sinisalo J, Lüscher TF. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37:1967–76.
Cordis GA, Yoshida T, Das DK. HPTLC analysis of sphingomylein, ceramide and sphingosine in ischemic/reperfused rat heart. J Pharm Biomed Anal. 1998;16:1189–93.
Kang SC, Kim BR, Lee SY, Park TS. Sphingolipid metabolism and obesity-induced inflammation. Front Endocrinol. 2013;4:67.
Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125–31.
Breckenridge WC, Halloran JL, Kovacs K, Silver MD. Increase of gangliosides in atherosclerotic human aortas. Lipids. 1975;10:256–9.
Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res. 2002;43:205–14.
Chatterjee S, Bedja D, Mishra S, Amuzie C, Avolio A, Kass DA, Berkowitz D, Renehan M. Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/- mice and rabbits fed a high-fat and -cholesterol diet. Circulation. 2014;129:2403–13.
Glaros EN, Kim WS, Rye KA, Shayman JA, Garner B. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res. 2008;49:1677–81.
Lopes-Virella MF, Baker NL, Hunt KJ, Hammad SM, Arthur J, Virella G, Klein RL, DCCT/EDIC Research Group. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019;13(3):481–91.
Knapp M, Lisowska A, Zabielski P, Musiał W, Baranowski M. Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat. 2013;106:53–61.
Egom EE, Mamas MA, Chacko S, Stringer SE, Charlton-Menys V, El-Omar M, Chirico D, Clarke B, Neyses L, Cruickshank JK, Lei M, Fath-Ordoubadi F. Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol. 2013;4:130.
Sattler K, Gräler M, Keul P, Weske S, Reimann CM, Jindrová H, Kleinbongard P, Sabbadini R, Bröcker-Preuss M, Erbel R, Heusch G, Levkau B. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66:1470–85.
Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55–63.
Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29:381–402. PubMed: 18451260.
Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, Summers SA. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem. 2003;278:10297–303.
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015–25.
Schilling JD, Machkovech HM, He L, Sidhu R, Fujiwara H, Weber K, Ory DS, Schaffer JE. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J Biol Chem. 2013;288:2923–32.
Davis CN, et al. IL-1beta induces a MyD88-dependent and ceramide-mediated activation of Src in anterior hypothalamic neurons. J Neurochem. 2006;98:1379–89.
Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988;240:1546–8.
Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med. 1986;164:1301–9.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998–5004.
Daffu G, del Pozo CH, O’Shea KM, Ananthakrishnan R, Ramasamy R, Schmidt AM. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci. 2013;14(10):19891–910.
Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med. 2009;87(3):235–47.
Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994;91(19):8807–11.
Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab. 2000;11(9):368–75.
Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17(7):983–96.
Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26(12):2716–23.
Rios FJ, Koga MM, Ferracini M, Jancar S. Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation. PLoS One. 2012;7(5):e36632.
Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol. 2010;134(1):5–24.
Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.
Virella G, Muñoz JF, Galbraith GMP, Gissinger C, Chassereau C, Lopes-Virella MF. Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol. 1995;75:179–89.
Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006;47(9):1975–83.
Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010;5(9):e12534.
Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM. Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology. 2012;136(1):30–45.
Virella G, Wilson K, Elkes J, Hamma SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018;187:1–9.
Rhoads JP, Lukens JR, Wilhelm AJ, et al. Oxidized LDL-immune complex priming of the Nlrp3 inflammasome involves TLR and FcγR cooperation and is dependent on CARD9. J Immunol. 2017;198:2105–14.
Li Y, Lu Z, Huang Y, Lopes-Virella MF, Virella G. F(ab′)2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016;173:50–6.
Lu Z, Zhang X, Li Y, Lopes-Virella MF, Huang Y. TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology. 2015;220(11):1246–54.
Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 1989;243:393–6.
Stevenson HC, Dekaban GA, Miller PJ, Benyajati C, Pearson ML. Analysis of human blood monocyte activation at the level of gene expression. J Exp Med. 1985;161:503–13.
Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H. Localization of PDGF-b protein in macrophages in all phases of atherogenesis. Science. 1990;248:1009–12.
Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn M. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987;84:6020–4.
Werb Z, Bonda MJ, Jones PA. Degradation of connective tissue matrices by macrophages: I. Proteolysis of elastin, glycoproteins, and collagens by proteinases isolated from macrophages. J Exp Med. 1980;152:1340–57.
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618–23.
Breviario F, Bertocchi F, Dejana E, Bussolino F. IL-1 induced adhesion of polymorphonuclear leukocytes to cultured human endothelial cells. Role of platelet-activating factor. J Immunol. 1988;141:3391–7.
Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Homback V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary heart disease. Circulation. 2003;107:1954–7.
Bertrand MJ, Tardif JC. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opin Emerg Drugs. 2017;22(1):1–26.
Falk E. Why do plaques rupture? Circulation. 1992;86(Suppl III):30–42.
Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrow MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-moderate coronary artery disease? Circulation. 1988;78:1157–66.
Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–50.
Amento EP, Ehsani N, Palmer H, Libby L. Cytokine positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1223–30.
Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaques. Am J Pathol. 1989;135:169–75.
Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126–46.
Morton LF, Barnes MJ. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis. 1982;42:41–51.
Matrisian LM. The matrix-degrading metalloproteinases. BioEssays. 1992;14:455–63.
Sukhova G, Schoenbeck U, Rabkin E, Schoen FJ, Poole AR, Billinhurst RC, Libby P. Colocalization of the interstitial collagenase MMP-1 & MMP-13 with sites of cleaved collagen indicates their role in plaque destabilization. Circulation (Suppl). 1998;98:48.
Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2640–7.
Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2000;20:2533–8.
Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis. 2001;156:119–25.
Li Y, Devadoss JS, Sundararaj KP, Lopes-Virella MF, Huang Y. IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J Cell Biochem. 2010;110(1):248–59.
Sundararaj P, Samuvel DJ, Li Y, Sanders JJ, Lopes-Virella MF, Huang Y. Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J Biol Chem. 2009;284(20):13714–24.
Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Homback V, Koenig W. Antidiabetic PPAR – activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:283–8.
Li Y, Samuvel DJ, Sundararaj KP, Lopes-Virella MF, Huang Y. IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J Cell Biochem. 2010;110(1):248–59.
Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med. 2000;6:790–6.
Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost. 2001;86:420–6.
Moons AH, Levi M, Peters RJ. Tissue factor and coronary heart disease. Cardiovasc Res. 2002;53:313–25.
Marchini JF, Manica A, Crestani P, Dutzmann J, Folco EJ, Weber H, Libby P, Croce K. Oxidized low-density lipoprotein induces macrophage production of prothrombotic microparticles. J Am Heart Assoc. 2020;9(15):e015878.
Colwell JA. Antiplatelet drugs and prevention of macrovascular disease in diabetes mellitus. Metabolism. 1992;41(Suppl 1):7–10.
Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121.
Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010;7(4):260–73.
Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J. 2010;74:3–12.
Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood. 2002;99:4475–85.
Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198–206.
Ibbotson SH, Catto A, Davies JA, Grant PJ. The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thromb Haemost. 1995;73:243–6.
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.
Karatela RA, Sainani GS. Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). Diabetes Res Clin Pract. 2009;84:e41–4.
Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA. 1987;258:1183–6.
Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1–11.
Green D, Chan C, Kang J, Liu K, Schreiner P, Jenny NS, Tracy RP. Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study. J Thromb Haemost. 2010;8:489–95.
Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT. DCCT/ECIC study group. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003;26:1439–48.
Hornsby WG, Boggess KA, Lyons TJ, Barnwell WH, Lazarchick J, Colwell JA. Hemostatic alterations with exercise conditioning in NIDDM. Diabetes Care. 1990;13:87–92.
Ceriello A, Esposito K, Ihnat M, Zhang J, Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. J Thromb Haemost. 2009;7:1228–30.
Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31:1590–5.
Rosove MH, Frank HJL, Harwing SSL. Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care. 1984;7:174–9.
Ceriello A, Giugliano D, Quatraro A, Marchi E, Barbanti M, Lefebvre P. Evidence for a hyperglycemia-dependent decrease of antithrombin complex formation in humans. Diabetologia. 1990;33:163–7.
Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed antithrombin III activity by non-enzymatic glycosylation: possible role in fibrin deposition in diabetes. Diabetes. 1984;33:532–5.
Vukovich TC, Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes. 1986;35:617–9.
Booyse FM, Bruce R, Gianturco SH, Bradley WA. Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells. Semin Thromb Hemost. 1988;14:175–9.
Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990;10:1067–73.
Juhan-Vague I, Alessi MC. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost. 1999;82:832–6.
Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–7.
Sakamoto TJ, Woodcock-Mitchell K, Marutsuka JJ, Mitchell BE, Sobel FS. TNF-alpha and insulin. Alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Phys. 1999;276:C1391–7.
Okada HJ, Woodcock-Mitchell J, Mitchell T, Sakamoto K, Marutsuka BE, Sobel FS. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation. 1998;97:2175–82.
Feener EP, Northup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and –2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353–62.
Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation. 1993;88:2030–4.
Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493–8.
Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia AA. Hypofibrinolysis associated with vasculopathy in non-insulin dependent diabetes mellitus. Thromb Res. 1990;59:51–9.
Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21:611–7.
Gray RP, Patterson DLH, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arteriosclerosis. 1993;13:415–20.
Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994;17:818–23.
Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995;18:1150–5.
Sahli D, Eriksson JW, Boman K, Svensson MK. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res. 2009;123:701–6.
Brommer EJ, Gevers Leuven JA, Barrett-Bergshoeff MM. Response of fibrinolytic activity and factor VIII-related antigen to stimulation with desmopressin in hyperlipoproteinemia. J Lab Clin Med. 1982;100:105–14.
Juhan-Vague I, Vague P, Poisson C, Aillaud MF, Mendez C, Collen D. Effect of 24 hours of normoglycemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetes. Thromb Haemost. 1984;51:97–8.
Zaman AKMT, Fujii S, Sawa H, Goto D, Tshimori N, Watano K, Kaneko T, Furumoto T, Sugawara T, Sakuma I, Kitabatake A, Sobel BE. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation. 2001;103:3123–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lopes-Virella, M.F., Virella, G. (2023). Diabetes and Atherosclerosis. In: Johnstone, M., Veves, A. (eds) Diabetes and Cardiovascular Disease. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-031-13177-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-13177-6_9
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-031-13176-9
Online ISBN: 978-3-031-13177-6
eBook Packages: MedicineMedicine (R0)